Rigel Pharmaceuticals, Inc.RIGLNASDAQ
Loading
Revenue Growth Recovery in ProgressRecovering
Percentile Rank56
3Y CAGR-84.4%
5Y CAGR+8.1%
Year-over-Year Change
Year-over-year revenue growth rate
3Y CAGR
-84.4%/yr
vs +8.0%/yr prior
5Y CAGR
+8.1%/yr
Recent deceleration
Acceleration
-92.4pp
Decelerating
Percentile
P56
Within normal range
vs 5Y Ago
1.5x
Solid growth
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 0.49% |
| Q3 2025 | -31.69% |
| Q2 2025 | 90.66% |
| Q1 2025 | -7.40% |
| Q4 2024 | 4.14% |
| Q3 2024 | 50.12% |
| Q2 2024 | 24.74% |
| Q1 2024 | -17.48% |
| Q4 2023 | 27.22% |
| Q3 2023 | 4.64% |
| Q2 2023 | 3.13% |
| Q1 2023 | -49.16% |
| Q4 2022 | 128.82% |
| Q3 2022 | -24.85% |
| Q2 2022 | 78.18% |
| Q1 2022 | -18.00% |
| Q4 2021 | -5.26% |
| Q3 2021 | -17.98% |
| Q2 2021 | -67.58% |
| Q1 2021 | 339.12% |
| Q4 2020 | 0.33% |
| Q3 2020 | 14.78% |
| Q2 2020 | -71.27% |
| Q1 2020 | 262.08% |
| Q4 2019 | -26.16% |
| Q3 2019 | 100.41% |
| Q2 2019 | -17.56% |
| Q1 2019 | -66.65% |
| Q4 2018 | 678.15% |
| Q3 2018 | 172.24% |
| Q2 2018 | 0.00% |
| Q1 2018 | 0.00% |
| Q4 2017 | -100.00% |
| Q3 2017 | 0.00% |
| Q2 2017 | -100.00% |
| Q1 2017 | 19.47% |
| Q4 2016 | -20.21% |
| Q3 2016 | -56.25% |
| Q2 2016 | 70.89% |
| Q1 2016 | -41.09% |